1. Oral administration of non‐absorbable delayed release 6‐mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. (August 2015) Authors: Israeli, E.; Goldin, E.; Fishman, S.; Konikoff, F.; Lavy, A.; Chowers, Y.; Melzer, E.; Lahat, A.; Mahamid, M.; Shirin, H.; Nussinson, E.; Segol, O.; Ya'acov, A. Ben; Shabbat, Y.; Ilan, Y. Journal: Clinical and experimental immunology Issue: Volume 181:Number 2(2015:Aug.) Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Oral administration of non‐absorbable delayed release 6‐mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. (August 2015) Authors: Israeli, E.; Goldin, E.; Fishman, S.; Konikoff, F.; Lavy, A.; Chowers, Y.; Melzer, E.; Lahat, A.; Mahamid, M.; Shirin, H.; Nussinson, E.; Segol, O.; Ya'acov, A. Ben; Shabbat, Y.; Ilan, Y. Journal: Clinical and experimental immunology Issue: Volume 181:Number 2(2015:Aug.) Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗